JP2018500332A5 - - Google Patents

Download PDF

Info

Publication number
JP2018500332A5
JP2018500332A5 JP2017532140A JP2017532140A JP2018500332A5 JP 2018500332 A5 JP2018500332 A5 JP 2018500332A5 JP 2017532140 A JP2017532140 A JP 2017532140A JP 2017532140 A JP2017532140 A JP 2017532140A JP 2018500332 A5 JP2018500332 A5 JP 2018500332A5
Authority
JP
Japan
Prior art keywords
antibody
composition according
dose
ctla
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017532140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500332A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/066177 external-priority patent/WO2016100561A2/en
Publication of JP2018500332A publication Critical patent/JP2018500332A/ja
Publication of JP2018500332A5 publication Critical patent/JP2018500332A5/ja
Priority to JP2021131637A priority Critical patent/JP2021181482A/ja
Pending legal-status Critical Current

Links

JP2017532140A 2014-12-16 2015-12-16 中枢神経系新生物における免疫チェックポイント阻害剤の使用 Pending JP2018500332A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021131637A JP2021181482A (ja) 2014-12-16 2021-08-12 中枢神経系新生物における免疫チェックポイント阻害剤の使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462092783P 2014-12-16 2014-12-16
US62/092,783 2014-12-16
US201562261130P 2015-11-30 2015-11-30
US62/261,130 2015-11-30
PCT/US2015/066177 WO2016100561A2 (en) 2014-12-16 2015-12-16 Use of immune checkpoint inhibitors in central nervous systems neoplasms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021131637A Division JP2021181482A (ja) 2014-12-16 2021-08-12 中枢神経系新生物における免疫チェックポイント阻害剤の使用

Publications (2)

Publication Number Publication Date
JP2018500332A JP2018500332A (ja) 2018-01-11
JP2018500332A5 true JP2018500332A5 (enExample) 2019-01-31

Family

ID=56127849

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017532140A Pending JP2018500332A (ja) 2014-12-16 2015-12-16 中枢神経系新生物における免疫チェックポイント阻害剤の使用
JP2021131637A Pending JP2021181482A (ja) 2014-12-16 2021-08-12 中枢神経系新生物における免疫チェックポイント阻害剤の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021131637A Pending JP2021181482A (ja) 2014-12-16 2021-08-12 中枢神経系新生物における免疫チェックポイント阻害剤の使用

Country Status (9)

Country Link
US (3) US20180133313A1 (enExample)
EP (1) EP3233123A4 (enExample)
JP (2) JP2018500332A (enExample)
CN (1) CN106999590A (enExample)
BR (1) BR112017010101A2 (enExample)
CA (1) CA2969338A1 (enExample)
MX (1) MX2017007390A (enExample)
RU (1) RU2726996C1 (enExample)
WO (1) WO2016100561A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2746805T3 (es) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
ES2861352T3 (es) * 2015-04-28 2021-10-06 Bristol Myers Squibb Co Tratamiento del melanoma positivo para PD-L1 utilizando un anticuerpo anti-PD-1
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
MY187739A (en) 2015-08-11 2021-10-18 Wuxi Biologics Cayman Inc Novel anti-pd-1 antibodies
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
WO2017176925A1 (en) 2016-04-05 2017-10-12 Bristol-Myers Squibb Company Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
CN109476748B (zh) * 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
GB201618291D0 (en) * 2016-10-28 2016-12-14 Bergen Teknologioverf�Ring As Novel immunotherapeutic treatments for tumours
MX2019006523A (es) * 2016-12-05 2019-10-15 G1 Therapeutics Inc Conservacion de respuesta inmunitaria durante regimenes de quimioterapia.
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
US11013802B2 (en) 2016-12-07 2021-05-25 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
DE102017119868B4 (de) * 2017-07-12 2021-05-27 Bruker Daltonik Gmbh Feuchtestabilisierung bei der Präparation von Proben für die Spektrometrie
US10617667B2 (en) * 2017-11-01 2020-04-14 Ono Pharmaceutical Co., Ltd. Method for treating brain tumors
KR20200139724A (ko) * 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
KR20210018253A (ko) 2018-05-31 2021-02-17 오노 야꾸힝 고교 가부시키가이샤 면역 체크포인트 저해약의 유효성 판정 바이오마커
WO2020191240A1 (en) * 2019-03-19 2020-09-24 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor
EP4028052A1 (en) * 2019-09-10 2022-07-20 Novocure GmbH A method of reducing viability of cancer cells by applying alternating electric fields and administering checkpoint inhibitors to the cancer cells
WO2021127254A1 (en) * 2019-12-19 2021-06-24 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
AU2020414040A1 (en) * 2019-12-27 2022-08-18 Zeria Pharmaceutical Co., Ltd. Cancer treatment method and medicine
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
US20230255978A1 (en) * 2020-05-12 2023-08-17 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022032312A1 (en) * 2020-08-07 2022-02-10 Northwestern University Methods of treating malignant glioblastoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54233B1 (sr) * 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
BRPI0919377A2 (pt) * 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
RU2402360C1 (ru) * 2009-07-08 2010-10-27 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Способ лечения злокачественной глиомы головного мозга
CN102178676B (zh) * 2011-04-29 2012-07-25 山东大学 一种治疗脑胶质瘤的药物组合物
AU2012273182A1 (en) * 2011-06-21 2014-01-16 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
US9212224B2 (en) * 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US10392442B2 (en) * 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

Similar Documents

Publication Publication Date Title
JP2018500332A5 (enExample)
Aglietta et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
JP2019503387A5 (enExample)
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
JP2019517512A5 (enExample)
RU2016148927A (ru) Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства
JP2018522887A5 (enExample)
JP2017507155A5 (enExample)
HRP20231156T1 (hr) Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka
US10842743B2 (en) Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents
CA2939464A1 (en) Use of anti-ccr5 antibodies in graft versus host disease
HRP20210399T1 (hr) Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)
JP2018514550A5 (enExample)
JP2018516969A5 (enExample)
JP2018515474A5 (enExample)
RS59134B1 (sr) Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća
JP2014533279A5 (enExample)
JP2015534577A5 (enExample)
JP2015534580A5 (enExample)
HRP20181646T2 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
JP2019517505A5 (enExample)
JP2015534578A5 (enExample)
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
JP2019522657A5 (enExample)
JP2025185043A (ja) 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与